Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Shares of Sarepta Therapeutics (SRPT) were moving ahead more than 5% in recent trading, following positive data about its Duchenne muscular dystrophy drug eteplirsen. This morning, Sarepta announced that a Phase IIb study of the treatment showed that patients at 84 weeks showed continued stabilization of walking ability. Patients on the drug were able to walk longer distances than those taking a placebo. Needham & Co.’s Chad Messer weighed in on the news today, noting that the data continue to support the case for the drug’s long term safety and efficacy. He thinks that the Food and Drug Administration will allow Sarepta to apply for accelerated approval after their next update meeting in the third quarter.
Help employers find you! Check out all the jobs and post your resume.
